Kolexia
Poncelin De Raucourt Emmanuelle Biologie médicale
Poncelin De Raucourt Emmanuelle
Biologie médicale
Centre hospitalier de Versailles
Le Chesnay, France
41 Activités
0 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Hémophilie A Maladies de von Willebrand Déficit en facteur XI Hémorragie Hémarthrose Maladie grave COVID-19 Maladies du foie Fibrose

Collaborateurs

Voir plus
Flaujac Claire
Flaujac Claire
Centre hospitalier de Versailles, Le Chesnay, France
Desprez Dominique
Desprez Dominique
Hôpital Hautepierre, Strasbourg, France
Pan-Petesch Brigitte
Pan-Petesch Brigitte
Hôpital Morvan, Brest, France
Roussel-Robert Valerie
Roussel-Robert Valerie
Hôpital Cochin, Paris, France

Industries

Voir plus
LFB
8 collaboration(s)
Dernière en 2023
Takeda Pharmaceutical
6 collaboration(s)
Dernière en 2021
Schlesinger Group France
5 collaboration(s)
Dernière en 2023
A+A
3 collaboration(s)
Dernière en 2022

Dernières activités

Voir plus
SENIORHEMO: Objective and Perceived Health Status of Elderly People With Moderate or Severe Haemophilia in France: an Ancillary Study of the FranceCoag Registry
Essai Clinique (Assistance publique - Hôpitaux de Marseille)   07 juin 2023
121.1 Pregnancy in women with factor XI deficiency (<60 UI/dl) and use of neuraxial analgesia: Real life data in a French cohort of 314 pregnancies
Abstracts of the ISTH 2022 Congress of the International Society of Thrombosis and Haemostasis, July 9–13, 2022   21 octobre 2022
Use of prothrombin complex concentrates in severe liver disease: in vitro dose effects on haemostasis parameters: COPIH Study
Abstracts of the ISTH 2022 Congress of the International Society of Thrombosis and Haemostasis, July 9–13, 2022   21 octobre 2022
116.1 Usefulness of rotational plasma thromboelastometry in severe inherited FXIII deficiency
Abstracts of the ISTH 2022 Congress of the International Society of Thrombosis and Haemostasis, July 9–13, 2022   21 octobre 2022
92.1 Evaluation of four different reagents on the coagulation analyzers STAR MAX® and ATELLICA® COAG 360 for Emicizumab concentration measurement in severe hemophilia A patients
Abstracts of the ISTH 2022 Congress of the International Society of Thrombosis and Haemostasis, July 9–13, 2022   21 octobre 2022
PO158 EFFICACY AND SAFETY OF HIGH RATIO HVWF/FVIII CONCENTRATE (VONCENTO®) FOR THE TREATMENT OF BLEEDING EPISODES IN PATIENTS WITH VON WILLEBRAND DISEASE: THE OPALE FRENCH EXPERIENCE
15th Annual Congress of European Association for Haemophilia and Allied Disorders 2022, 2–4 February 2022, Virtual Meeting   31 janvier 2022
Resistance to Fibrinolysis in Critically Ill Patients with COVID-19 Can Be Overcome by N-acetylcysteine in vitro
Special Issue: Abstracts of the ISTH 2021 Virtual Congress of the International Society of Thrombosis and Haemostasis, July 17–21, 2021   07 octobre 2021
Population Pharmacokinetics Modelling of prescribed factors VIII in patients with severe haemophilia A: Toward a global model explaining the main variability of pharmacokinetic parameters
Abstracts of the Annual Meeting of French Society of Pharmacology and Therapeutics, 15–16 June 2021, E‐meeting, France   02 juin 2021
ABS219 | EFFICACY AND SAFETY OF A RECOMBINANT VON WILLEBRAND FACTOR TREATMENT IN PATIENTS WITH INHERITED VON WILLEBRAND DISEASE REQUIRING SURGICAL PROCEDURES: A FRENCH MULTICENTRE RETROSPECTIVE STUDY
Virtual Congress of the European Association for Haemophilia and Allied Disorders 2021 3‐5 February 2021   02 février 2021
ABS212 | DELIVERY MANAGEMENT OF A TYPE 3 VON WILLEBRAND DISEASE WITH A POTENTIAL ALLO-IMMUNISATION WITH RECOMBINANT VWF, VONICOG ALPHA, AND FACTOR VIII CONCENTRATES.
Virtual Congress of the European Association for Haemophilia and Allied Disorders 2021 3‐5 February 2021   02 février 2021